New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 14, 2012
07:44 EDTINCY, LLYIncyte weakness creates buying opportunity, says Oppenheimer
After Incyte (INCY) and partner Eli Lilly (LLY) reported Phase IIb results for their baricitinib in rheumatoid arthritis, Oppenheimer expects the drug to be approved in 2015-2016. The firm thinks the baricitinib program is doing well, and it maintains a $23 price target and Outperform rating on Incyte.
News For INCY;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 5, 2015
13:01 EDTINCYNomura sees more M&A following AbbVie's acquisition of Pharmacyclics
Nomura believes AbbVie's (ABBV) acquisition of Pharmacyclics (PCYC) supports its call that Receptos (RCPT) and Infinity Pharmaceuticals (ICPT) are on the top of M&A lists given both companies have potential $5B in peaks sales potential and unencumbered assets. Additionally, the firm believes the deal has positive implications for Neutral rated Incyte (INFI) given the potential AbbVie can now evaluate ABT-199 in combination with Incyte's duvelisib and Pharmacyclic's Imbruviea across a range of hematological malignancies.
March 4, 2015
09:07 EDTLLYFDA making testosterone product makers change labeling
Subscribe for More Information
March 3, 2015
08:04 EDTLLYDenovo Biopharma licensed Pomaglumetad Methionil from Eli Lilly
Subscribe for More Information
07:16 EDTLLYCowen to hold a conference
35th Annual Health Care Conference is being held in Boston on March 2-4 with webcasted company presentations to begin on March 3 at 8 am; not all company presentations may be webcasted. Webcast Link
March 2, 2015
08:53 EDTLLYNon-profit gives lukewarm review to MannKind inhaled insulin, TheStreet says
Subscribe for More Information
07:31 EDTINCYIncyte appoints Steven Stein as Chief Medical Officer
Subscribe for More Information
February 26, 2015
07:37 EDTINCYIncyte to sponsor U.S. polycythemia vera study
Incyte announced that it is sponsoring the first major observational study of patients living with polycythemia vera in the U.S. PV is a rare and progressive blood cancer that can lead to debilitating symptoms, serious cardiovascular complications, and death.The REVEAL study will seek to describe the real-world clinical burden of PV and how healthcare services are utilized in the management of this disease. Incyte is partnering with approximately 200 community and academic medical centers to conduct the study in the U.S. REVEAL, which recently began enrolling patients, is expected to include 2,000 patients under the supervision of a physician for the active management of PV for a period of three years.
February 24, 2015
06:34 EDTLLYEli Lilly CEO states company is not for sale, Financial Times says
Subscribe for More Information
February 23, 2015
08:31 EDTLLYEli Lilly announces delay in submission of basal insulin peglispro beyond Q1
Subscribe for More Information
07:30 EDTINCYIncyte price target raised to $89 from $75 at Oppenheimer
Oppenheimer increased its price target on Incyte after the company reported that sales of its flagship Jakafi drug had jumped 46% year-over-year in Q4. The firm continues to be upbeat on Jakafi's revenue outlook and the company's pipeline. It keeps an Outperform rating on the shares.
07:06 EDTLLY, INCYEli Lilly and Incyte announces positive results for baricitinib
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use